2014 Fall CLU Highlights
Enzyme Replacement Therapy for Lipid Storage Disorders
W. Virgil Brown, MD, Robert J. Desnick, PhD, MD, and Gregory A. Grabowski MD
W. Virgil Brown, MD, Robert J. Desnick, PhD, MD, and Gregory A. Grabowski, MD discuss JCL Roundtable: Enzyme replacement therapy for lipid storage disorders.
Tags:
Advancing Therapy in the Severe FH Patient
Anne Carol Goldberg, MD, FACP, FAHA, FNLA, Joyce L. Ross, MSN, CRNP, CS, FNLA, FPCNA, and James A. Underberg MS, MD, FACP, FACPM,FNLA
Anne Carol Goldberg, MD, FACP, FAHA, FNLA presents Identification of the Patient with Familial Hypercholesterolemia: Genotypic and Phenotypic Considerations.
Joyce L. Ross, MSN, CRNP, CS, FNLA, FPCNA presents Clinical Evaluation of the Severe FH Patient and Treatment Considerations.
James A. Underberg MS, MD, FACP, FACPM,FNLA presents New Treatments for Homozygous Familial Hypercholesterolemia .
Tags:
NLA Recommendations for Patient-Centered Management of Dyslipidemia
Carl E. Orringer, MD, FACC, FNLA
Carl E. Orringer, MD, FACC, FNLA presents NLA Recommendations for Patient-Centered Management of Dyslipidemia.
Tags:
Data Supported Evidence for Differences in the ACC/AHA Guidelines and NLA Recommendations for Dyslipidemia Management
Kevin C. Maki, PhD, CLS, FNLA
Kevin C. Maki, PhD, CLS, FNLA presents Data Supported Evidence for Differences in the ACC/AHA Guidelines and NLA Recommendations for Dyslipidemia Management.
Tags:
Current & Future Triglyceride Pharmaceuticals
Harold E. Bays, MD, FNLA
Harold E. Bays, MD, FNLA presents Current & Future Triglyceride Pharmaceuticals.
Tags:
